Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
News provided by
Share this article
Up to 200,000 Johnson & Johnson
Ebola vaccine regimens will be made available as part of a WHO early access clinical program now underway in Sierra Leone
Company s Ebola vaccine regimen also receives Prequalification from the WHO
The Johnson & Johnson vaccine regimen is designed to be used proactively to induce immunity against Ebola in adults and children
NEW BRUNSWICK, N.J., May 13, 2021 /PRNewswire/ Johnson & Johnson (NYSE: JNJ) (the Company) today announced the World Health Organization (WHO) and the government of Sierra Leone have begun administering the Company s Ebola vaccine regimen as part of a WHO early access clinical program aimed at preventing further spread of Ebola in West Africa. The vaccine regimen, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) in collaboration with Bavarian Nordic A/S,